ONY Enters into Co-Promotion Agreement with Recordati Rare Diseases for NeoProfen [Health & Beauty Close - Up]
(Health & Beauty Close - Up Via Acquire Media NewsEdge) ONY, Inc., a provider of neonatal pharmaceutical development, has reached an agreement with Recordati Rare Diseases to co-promote NeoProfen (ibuprofen lysine) Injection.
According to a release, NeoProfen is indicated to close a clinically significant Patent Ductus Arteriosis (PDA) in premature infants weighing between 500 and 1500 grams, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective.
ONY is the manufacturer and marketer of Infasurf (calfactant) a lung surfactant for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
"The co-promotion provides ONY a second product used exclusively in Neonatal Intensive Care Units, and continues the company's commitment to neonatology," said John Librie, CEO, ONY. "Recordati Rare Diseases is an excellent partner that shares the priorities of ONY and whose expertise is complementary to ONY's strengths."
"We have evaluated all of the scientific and medical evidence available for NeoProfen and believe it is an excellent and important neonatology product for the treatment of Patent Ductus Arteriosus. We are proud to be able to represent NeoProfen to those caring for premature babies with Patent Ductus Arteriosus," said Edmund A. Egan, M.D., ONY Chairman and Chief Medical Officer.
((Comments on this story may be sent to email@example.com))
(c) 2014 ProQuest Information and Learning Company; All Rights Reserved.
[ Back To TMCnet.com's Homepage ]